Merck locks into omeprazole proton pump inhibitor family profits until 2017 under a renegotiated joint venture agreement with Astra, the company announces June 19. Merck will continue to receive revenues from the PPI, both Rx and OTC, and the potential Rx successor perprazole through 2017 if sales meet a minimum threshold. Astra Merck announced plans for an OTC switch of omeprazole for heartburn Dec. 15 under a marketing deal with Procter & Gamble ("The Tan Sheet" Dec. 23, 1997, p. 2). Astra and Merck currently share profits equally from all joint venture sales, including Prilosec. Under the renegotiated deal, Merck and Astra Merck USA will be merged into one company, Astra Pharmaceuticals, under the operational control of Astra. Merck will receive a $1.4 bil. cash loan from Astra at the close of the restructuring, targeted for July 1. Astra has the option to buy out Merck's share after 2008, excluding Prilosec and perprazole...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Six deaths early in treatment inspired a new safety requirement for Biogen/Eisai’s Leqembi to promote early identification of patients affected by the well-known risk of amyloid-related imaging abnormalities with edema (ARIA-E).
The CBER director rejected Pfizer’s assertions that pediatric dosing gaps, supply constraints and comparative mRNA content justify keeping the vaccine under emergency use authorization for younger children.
The agency is creating two new AI councils to facilitate its role in responsible AI adoption and regulation.
